Post sphinterotomy-bleeding (PSB) occurs in 1-2 % of Endosocpic Retrograde Cholangiopancreaticography (ERCP) and usually needs no blood transfusion after endoscopic therapy but can be life-threatening in some rare cases. There are no prospective comparative studies concerning the endoscopic treatment of PSB due to the rarity of the incident. Insertion of an endoprosthesis in the common bile duct may be more effective than Epinephrin-injection into the papilla which is the therapy of first choice. A retrospective single centre analysis on both used methods over a study period of 16 years shall be performed.
Post sphinterotomy-bleeding (PSB) occurs in 1-2 % of Endosocpic Retrograde Cholangiopancreaticography (ERCP) and usually needs no blood transfusion after endoscopic therapy but can be life-threatening in some rare cases. The increasing use of antiplatelet and/or anticoagulant therapies enhances the risk of PSB. There are no prospective comparative studies concerning the endoscopic treatment of PSB due to the rarity of the incident. Insertion of an endoprosthesis in the common bile duct may be more effective than Epinephrin-injection into the papilla which is the therapy of first choice. A retrospective single centre analysis on both used methods over a study period of 16 years shall be performed. In detail, clinical success and safety of the procedure, re-bleeding rate, number of re-interventions and days of hospital stay will be analysed.
Study Type
OBSERVATIONAL
Enrollment
100
Tertiary referral hospital: Theresienkrankenhaus und St. Hedwig Hospital, Academic
Mannheim, Germany
Clinical success
No re-bleeding occurs in the follow-up that requirers a further interventional treatment of re-bleeding (any endoscopic, radiological embolization or surgery): yes/no
Time frame: From the successful endocopic treatment of post sphincterotomy-bleeding up to 30 days in the follow up
Re-interventions
Amount of endoscopic re-interventions (further endoscopic therapy of re-bleeding of the papilla, removal or exchange of the plastic stent): number (n)
Time frame: From the endoscopic treatment of post-sphincterotomy-bleeding up to three months
Hospital stay after treatment
Hospital stay (days) after treatment of post sphincterotomy-bleeding
Time frame: From the endoscopic treatment of post-sphincterotomy-bleeding up to 30 days
Post ERCP-pancreatitis
Any kind of post ERCP-pancreatitis that occurs after treatment of post sphincterotomy-bleeding and can be refered to this treatment (patients with cannulated pancreatic duct are excluded): yes/no
Time frame: From the endoscopic treatment of post-sphincterotomy-bleeding up to three days
Increasing of cholestasis parameters
Any kind of cholestasis measured by an increase of bilirubin level (mg/dl) after the treatment of post-sphincterotomy-bleeding that can be refered to this treatment (patients with unsuccesful endoscopic drainage/stone extraction are excluded): yes/no
Time frame: From treatment of post-sphincterotomy-bleeding up to three days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.